Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft

Nephrology Dialysis Transplantation

Volumn 13, Issue 10, 1998, Pages 2601-2604

  Grinyó, Josep M ^a   Gil Vernet, Salvador ^a   Seron, Daniel ^a   Hueso, Miquel ^a   Fulladosa, Xavier ^a   Cruzado, Josep M ^a   Moreso, Francesc ^a   Fernandez, Amparo ^a   Torras, Joan ^a   Riera, Lluis ^a   Castelao, Alberto M ^a   Alsina, Jeroni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antithymocyte globulin; Mycophenolate mofetil; Suboptimal grafts

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; ANTILYMPHOCYTE SERUM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0347812744     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.10.2601     Document Type: Article

References (20)

1. Novick Ac, Ho-Hsiegh H, Steinmuller D et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Transplantation 1986; 42: 154-158
2. Canafax DM, Torres A, Fryd DS et al. The effects of delayed function on recipients of cadaver renal allografts. Transplantation 1986; 41: 177-181
3. Lewis RM. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 1995; 48 [Suppl 52]: S75-S78
4. Klintmalm G, Bohan SO, Sundelin B, Wilczeck H. Interstitial fibrosis in renal allograft after 12 to 46 months of cyclosporine treatment: beneficial effect of low doses in early posttransplant period. Lancet 1984; 2: 950-954
5. Serón D, Moreso F, Bover J et al. Early protocol renal allograf biopsies and graft outcome. Kidney Int 1997; 51: 310-316
6. Myers BD, Ross J, Newton L, Luetscher J, Perloth M. Cyclosporine-associated chronic nephropathy. N Engl J. Med 1984; 311: 609-705
7. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D. Cyclosporine-associated endstage nephropathy after cardiac transplantation. Transplantation 1997; 63: 664-668
8. Bennet WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achiles' heel of immuno-suppressive therapy. Kidney Int 1996; 50: 1089-1100
9. Remuzzi G, Perico N. Cyclosporine-induced dysfunction in experimental animals and humans. Kidney Int 1995; 48 [Suppl 52]: S70-74
10. Wyner LM, McElroy JB, Kodge EE, Peidmonte M, Novick AC. Use of kidneys from older cadaver donors for renal transplantation. Urology 1993; 41: 107-110
11. Gaber LW, Moore LW, Alloway RR, Amiri MH, Vera SR, Gaber AO. Glomerulosclerosis as a determinant of posttransplant function of older donor renal allografts. Transplantation 1995; 60: 334-339
12. Leunissen KM, Bosman FT, Nieman FH et al. Amplification of the nephrotoxic effect of cyclosporine by preexistent chronic histological lesions in the kidney. Transplantation 1989; 48: 590-593
13. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325
14. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232
15. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037
16. Grino JM, Alsina J, Sabater R et al. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Transplantation 1990; 49: 1114-1117
17. Solez K, Axelsen SA, Benediktsson H et al. International standarization of criteria for the histologic diagnosis of renal allograf rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-422
18. Paul LC, Muzaffar S, Valentin J-F. Donor treatment with mycophenolate mofetil protects against ischemia-reperfusion injury. J Am Soc Nephrol 1997; 8: 662A (abstract)
19. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7: 96-112
20. Kimball JA, Pescovitz MD, Book BK, Norman DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379-1383